no_english_version

no_arabic_version

Search

Request an Appointment
Find a Doctor
Find a Job
Give Now

Log in to Patient Account
English

Twitter
Facebook
Pinterest
YouTube

English

Menu
Search

Search

All Mayo Clinic Topics

Care at Mayo Clinic
Health Information
Featured conditions
Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
For Medical Professionals
Research
College of Medicine and Science
Giving to Mayo Clinic

Clinical Trials

Sections

Find Clinical Trials
About Clinical Studies
Volunteering
Diversity
Language Assistance
Resources
Contact

By condition, treatment or drug nameSearch tips

Perform a New Search

Filter Results

Locations

Rochester, MN
Scottsdale/Phoenix, AZ
Jacksonville, FL
La Crosse, WI
Eau Claire, WI
Mankato, MN
Albert Lea, MN
Austin, MN

Study status

(for at least one location)

Open/Status Unknown
Closed for Enrollment

Gender

Accepts males
Accepts females

Age

Age (edit) Age

Healthy Volunteer

What is this?

A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Accepts healthy volunteers

Study phase

What is this?

During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Phase: 0
Phase: 1 (1, 1/2)
Phase: 2 (1/2, 2, 2/3)
Phase: 3 (2/3, 3, 3/4)
Phase: 4 (3/4, 4, 4/5)

Search Results 601-603 of 603 for hematology

Edit search filters

A Study to Establish An Integrated Biomarker Panel for COVID-19 Infection Risk and Severity Prediction

Jacksonville, FL, Rochester, MN
- See Details
A Study to Establish An Integrated Biomarker Panel for COVID-19 Infection Risk and Severity Prediction
- Study type:
  Observational
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study

Aim 1: Determine the basal profile of non-genomic factors in patients at the time of exposure to SARS-CoV-2 and correlate with the three clinical patient outcome categories (A, B, C) as observed through their clinical course.

Hypothesis: Baseline cytokine (IL-1β, IL-6, IL-4, IL-10, IFN-g and TNF-a) and the immune cellular repertoire (helper/CD4+, cytotoxic/CD8+, T-regulatory cells, natural killer cells) constitute the inherent biologic immunity of an individual and underpins their vulnerability to SARS-CoV-2 infectivity and/or its subsequent sequalae.

Aim 2: Investigate if mutations or polymorphisms in genes (CXCR6, ACE2 and SLC6A20) linked to SARS-CoV-2 correlates with the three clinical patient outcome categories (A, B, C) as observed through their clinical course.

Hypothesis: ACE2 is a cellular receptor for SARS-CoV-2. The high binding affinity of ACE2 to SARS-CoV-2 is determined by its gene sequence and polymorphisms in the ACE2 gene itself or those that regulate ACE2 function (i.e. SLC6A20) can alter this binding potential and thus the clinical impact of the virus.

Aim 3: Develop an integrated model of non-genomic (Aim 1) and genomic (Aim 2) factors for prediction of the three potential clinical courses of an individual upon exposure to SARS-CoV-2.

Hypothesis: An integrated model incorporating quantitative analysis of cytokines/immune cells (Aim 1) and gene sequence analysis (Aim 2) will allow a more robust and accurate prediction for one of the three potential clinical courses (A, B, C) after SARS-CoV-2 exposure.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, FL

Closed for enrollment
View complete study & contact information

Rochester, MN

Closed for enrollment

Print study details
Site IRB:
21-001923
Immunogenicity And Safety Of Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Patients With Hematologic Malignancies And Associated Precursors

Rochester, MN
- See Details
Immunogenicity And Safety Of Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Patients With Hematologic Malignancies And Associated Precursors
- Study type:
  Observational
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study

The primary objective of this study is to determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies.

Secondary objectives of this study are to assess the safety of FDA approved COVID-19 vaccination in patients with hematologic malignancies, analyze the kinetics of immunogenic response over time after receipt of the COVID-19 vaccination. compare the immunogenicity of different COVID-19 vaccinations that will be approved by the FDA, and analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all participants and correlate with response to vaccination.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, MN

Closed for enrollment
View complete study & contact information

Print study details
Site IRB:
20-012589

NCT ID:
NCT04748185

Sponsor Protocol Number:
20-012589
Efficacy And Safety Of COVID-19 Vaccine In Cancer Patients

Jacksonville, FL
- See Details
Efficacy And Safety Of COVID-19 Vaccine In Cancer Patients
- Study type:
  Observational
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
About this study
We hypothesize that cancer patients on cytotoxic chemotherapy which affect immune response may not mount adequate immune response to COVID-19 vaccines.

Aims, purpose, or objectives:

To determine the antibody response to COVID-19 vaccine after vaccination.

To assess the adverse events of COVID-19 vaccines in cancer patients.

To determine the incidence and severity of COVID-19 infection after the vaccination.
Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, FL

Closed for enrollment
View complete study & contact information

Print study details
Site IRB:
21-001818

NCT ID:
NCT04865133

Sponsor Protocol Number:
21-001818

Pagination Clinical studies

Previous Page
Go to page 59
Go to page 60
Go to page 61

.

Mayo Clinic Footer

Request Appointment
Give Now
Contact Us
About Mayo Clinic
Employees
Site Map
About This Site

Legal Conditions and Terms

Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.

Terms and Conditions
Privacy Policy
Notice of Privacy Practices
Notice of Nondiscrimination
Manage Cookies

Advertising

Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.

Advertising and sponsorship policy
Advertising and sponsorship opportunities

Reprint Permissions

A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

© 1998-2026 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.